溢多利(300381) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 reached ¥402,535,465, an increase of 17.94% compared to ¥341,308,608 in the same period last year[8] - Net profit attributable to shareholders was ¥18,746,963, a significant turnaround from a loss of ¥18,154,900 in the previous year, representing a growth of 203.25%[8] - Net profit excluding non-recurring items was ¥13,088,046, compared to a loss of ¥21,131,641, marking an increase of 161.94%[8] - Basic earnings per share increased to ¥0.0426 from a loss of ¥0.0446, reflecting a growth of 195.52%[8] - The company reported a total comprehensive income of CNY 16,921,427.93 for Q1 2020, compared to a comprehensive loss of CNY 18,916,308.81 in the previous period[44] Cash Flow - Net cash flow from operating activities was ¥29,369,882, a substantial improvement of 587.79% from a negative cash flow of ¥6,021,009[8] - The net cash flow from financing activities was ¥155.47 million yuan, an increase of 151.35% year-on-year, mainly due to increased bank borrowings[17] - Cash inflow from operating activities amounted to ¥361,067,109.34, an increase from ¥269,187,713.73 in the previous period[50] - The net cash flow from financing activities was ¥155,472,762.26, compared to a negative cash flow of ¥302,794,354.12 in the previous period[52] - The net cash flow from investing activities was -¥43,598,895.66, an improvement from -¥197,055,860.25 in the previous period[51] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,746,030,010.79, up 5.05% from ¥4,518,083,187.45 at the end of the previous year[8] - Total liabilities increased to CNY 1,878,277,336.85 from CNY 1,789,323,009.37, which is an increase of approximately 5.0%[35] - The company's equity attributable to shareholders rose to CNY 2,599,667,087.41 from CNY 2,465,213,969.38, representing an increase of about 5.4%[36] - Short-term borrowings at the end of the period increased by 266.74 million yuan, a growth of 53.24%, mainly due to an increase in short-term bank loans[16] - The company's total assets as of Q1 2020 were CNY 2,948,160,454.03, an increase from CNY 2,797,074,739.65 in the previous period[42] Government Subsidies and Other Income - The company received government subsidies amounting to ¥7,465,988 during the reporting period[9] - The company received government subsidies that increased other income by 4.16 million yuan, a growth of 125.64% year-on-year[16] Operational Challenges and Adjustments - The company faces potential uncertainties in future operating performance due to the ongoing impact of the COVID-19 pandemic and disruptions in the global supply chain[20] - The company is adjusting its product structure to address the impact of African swine fever and is increasing marketing efforts in overseas markets[20] Investment and Fundraising - The total amount of raised funds for the quarter is 137,112.24 million, with a cumulative investment of 110,372.42 million[24] - The company adjusted the investment amount for the "New Hormone GMP Construction Project" from 400 million yuan to 309 million yuan, reducing the total fundraising amount by 91 million yuan, which accounts for 17.5% of the total fundraising[26] - The company plans to allocate the reduced fundraising of 91 million yuan to new projects, including 30 million yuan for the construction of a veterinary drug workshop at Hunan Chengda Biotechnology Co., 40 million yuan for GMP renovation at Henan Lihua Pharmaceutical Co., and 21 million yuan for acquiring 70% equity in Hunan Longteng Biotechnology Co.[26] Compliance and Management - The company has no violations regarding external guarantees during the reporting period[28] - There are no non-operating fund occupations by controlling shareholders or their related parties during the reporting period[29] - The company has conducted strict budget management to control procurement costs and reduce project implementation expenses, maximizing the efficiency of fundraising usage[27]